Clinical trial
Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With…
NCT00472199 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00472199 |
|---|---|
| Title | Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS) |
| Official title | A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | Pramipexole, Placebo |
| Enrollment | 331 |
| Start date | May 1, 2007 |
| Primary completion | Jul 1, 2008 |
| First posted | May 11, 2007 |
| Last update posted | Jun 27, 2014 |
| Countries | Austria, Belgium, Finland, Germany, Ireland, Netherlands, Slovakia, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: